1 Preface
2 Scope and Methodology
2.1 Objectives of the study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Generic Drug Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Region
5.4 Market Forecast
6 Global Generic Oncology Drug Market
6.1 Market Overview
6.2 Market Trends
6.3 Impact of COVID-19
6.4 Top Generic Oncology Drugs
6.5 Price Analysis
6.6 Market Forecast
6.7 SWOT Analysis
6.7.1 Overview
6.7.2 Strengths
6.7.3 Weaknesses
6.7.4 Opportunities
6.7.5 Threats
6.8 Value Chain Analysis
6.8.1 Research and Development
6.8.2 Manufacturing
6.8.3 Marketing
6.8.4 Distribution
6.9 Porter’s Five Forces Analysis
6.9.1 Overview
6.9.2 Bargaining Power of Buyers
6.9.3 Bargaining Power of Suppliers
6.9.4 Degree of Competition
6.9.5 Threat of New Entrants
6.9.6 Threat of Substitutes
6.9.7 Regulations in the Generics Industry
6.10 Key Market Drivers and Success Factors
7 Global Generic Oncology Drug Market: Performance of Key Regions
7.1 North America
7.2 Europe
7.3 Asia Pacific
7.4 Middle East and Africa
7.5 Latin America
8 Global Generic Oncology Drug Market: Competitive Landscape
8.1 Market Structure
8.2 Market Breakup by Key Players
8.3 Key Player Profiles
9 Generic Oncology Drug Manufacturing Process
9.1 Product Overview
9.2 Detailed Process Flow (Tablets)
9.3 Detailed Process Flow (Injectable)
9.4 Various Types of Unit Operations Involved
9.5 Mass Balance and Raw Material Requirements
10 Project Details, Requirements and Costs Involved
10.1 Land Requirements and Expenditures
10.2 Construction Requirements and Expenditures
10.3 Plant Machinery
10.4 Machinery Pictures
10.5 Raw Material Requirements and Expenditures
10.6 Packaging Requirements and Expenditures
10.7 Transportation Requirements and Expenditures
10.8 Utility Requirements and Expenditures
10.9 Manpower Requirements and Expenditures
10.10 Other Capital Investments
11 Loans and Financial Assistance
12 Project Economics
12.1 Capital Cost of the Project
12.2 Techno-Economic Parameters
12.3 Product Pricing and Margins Across Various Levels of the Supply Chain
12.4 Taxation and Depreciation
12.5 Income Projections
12.6 Expenditure Projections
12.7 Financial Analysis
12.8 Profit Analysis
Figure 2: Global: Generic Drug Market: Sales Value Trends (in Billion US$), 2017-2022
Figure 3: Global: Generic Drug Market Forecast: Sales Value Trends (in Billion US$), 2023-2028
Figure 4: Global: Generic Drug Market: Breakup by Region (in %), 2022
Figure 5: Global: Generic Oncology Drug Industry Overview
Figure 6: Global: Generic Oncology Drug Market: Sales Value Trends (in Billion US$), 2017-2022
Figure 7: Global: Generic Oncology Drug Market Forecast: Sales Value Trends (in Billion US$), 2023-2028
Figure 8: Global: Generic Oncology Drug Market: Breakup by Region (in %), 2022
Figure 9: Global: Generic Oncology Drug Industry: SWOT Analysis
Figure 10: Global: Generic Oncology Drug Industry: Value Chain Analysis
Figure 11: Global: Generic Oncology Drug Industry: Porter’s Five Forces Analysis
Figure 12: North America: Generic Oncology Drug Market (in Million US$), 2017, 2023 & 2028
Figure 13: Asia Pacific: Generic Oncology Drug Market (in Million US$), 2017, 2023 & 2028
Figure 14: Europe: Generic Oncology Drug Market (in Million US$), 2017, 2023 & 2028
Figure 15: Latin America: Generic Oncology Drug Market (in Million US$), 2017, 2023 & 2028
Figure 16: Middle East and Africa: Generic Oncology Drug Market (in Million US$), 2017, 2023 & 2028
Figure 17: Generic Oncology Drug Industry: Profit Margins at Various Levels of the Supply Chain
Figure 18: Generic Oncology Drug Manufacturing: Production Cost Breakup (in %)
Figure 19: Generic Oncology Drug Manufacturing Plant: Detailed Process Flow
Figure 20: Generic Oncology Drug Manufacturing Process: Conversion Rate of Feedstocks
Figure 21: Generic Oncology Drug Manufacturing Plant: Proposed Plant Layout
Figure 22: Generic Oncology Drug Manufacturing Plant: Breakup of Capital Costs (in %)
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer